Cargando…
COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205291/ https://www.ncbi.nlm.nih.gov/pubmed/34172379 http://dx.doi.org/10.1016/j.tracli.2021.06.001 |
| _version_ | 1783708479332024320 |
|---|---|
| author | Vuk, T. Hećimović, A. Jukić, I. Ravlić, S. Kurtović, T. Rnjak, D. Halassy, B. |
| author_facet | Vuk, T. Hećimović, A. Jukić, I. Ravlić, S. Kurtović, T. Rnjak, D. Halassy, B. |
| author_sort | Vuk, T. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8205291 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82052912021-06-16 COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits Vuk, T. Hećimović, A. Jukić, I. Ravlić, S. Kurtović, T. Rnjak, D. Halassy, B. Transfus Clin Biol Letter to the Editor Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. 2021-11 2021-06-15 /pmc/articles/PMC8205291/ /pubmed/34172379 http://dx.doi.org/10.1016/j.tracli.2021.06.001 Text en © 2021 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Vuk, T. Hećimović, A. Jukić, I. Ravlić, S. Kurtović, T. Rnjak, D. Halassy, B. COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits |
| title | COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits |
| title_full | COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits |
| title_fullStr | COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits |
| title_full_unstemmed | COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits |
| title_short | COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits |
| title_sort | covid-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205291/ https://www.ncbi.nlm.nih.gov/pubmed/34172379 http://dx.doi.org/10.1016/j.tracli.2021.06.001 |
| work_keys_str_mv | AT vukt covid19convalescentplasmatherapyforimmunodeficientpatientsweighinguprisksandbenefits AT hecimovica covid19convalescentplasmatherapyforimmunodeficientpatientsweighinguprisksandbenefits AT jukici covid19convalescentplasmatherapyforimmunodeficientpatientsweighinguprisksandbenefits AT ravlics covid19convalescentplasmatherapyforimmunodeficientpatientsweighinguprisksandbenefits AT kurtovict covid19convalescentplasmatherapyforimmunodeficientpatientsweighinguprisksandbenefits AT rnjakd covid19convalescentplasmatherapyforimmunodeficientpatientsweighinguprisksandbenefits AT halassyb covid19convalescentplasmatherapyforimmunodeficientpatientsweighinguprisksandbenefits |